Johnson & Johnson (JNJ) said Tuesday that new data from a phase 3 study showed the combination of Tecvayli and Darzalex Faspro cut the risk of disease progression or death by 83% in patients with relapsed or refractory multiple myeloma at almost three years of follow-up.
The company said the trial showed that 91% of patients who were progression-free at six months remained progression-free at three years.
The company also said the Tecvayli combination achieved higher rates across key secondary endpoints, including overall response, complete response, minimal residual disease negativity and overall survival, compared with standard of care. At three years, overall survival rate was 83.3% for the Tecvayli combination, Johnson & Johnson said.
The study compared Tecvayli plus Darzalex Faspro with combinations of Darzalex Faspro and dexamethasone with either pomalidomide or bortezomib in patients previously treated with one to three lines of therapy, according to the company.
Johnson & Johnson said it has submitted a supplemental biologics license application for the combination, which has received US Food and Drug Administration breakthrough therapy designation.
Shares of Johnson & Johnson were up 1.9% in recent Tuesday trading.
Price: 205.41, Change: +3.79, Percent Change: +1.88
Comments